Who Paid My Doc
Ran Schwarzkopf
Orange, CA Medical Doctor
NPI 1407016488 CMS profile 1297074
101 The City Dr S, Pavilion Iii, Building 29, Orange, CA 92868
General payments
$2,036,695
Research payments
$0
Ownership & investment interest
$607,435
Research they led as principal investigator
$3,324,524
Through program year 2025, Ran Schwarzkopf of Orange, CA is reported in the CMS Open Payments database as having received $2,036,695 across 907 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,324,524 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $607,435 across 13 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
14 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $429,337 | 160 | |
| 2024 | General | $458,339 | 204 | |
| 2023 | General | $392,600 | 157 | |
| 2022 | General | $248,755 | 131 | |
| 2021 | General | $183,389 | 82 | |
| 2020 | General | $124,080 | 45 | |
| 2019 | General | $200,196 | 128 | |
| 2025 | Ownership | $88,008 | 1 | |
| 2024 | Ownership | $86,571 | 2 | |
| 2023 | Ownership | $86,571 | 2 | |
| 2022 | Ownership | $86,571 | 2 | |
| 2021 | Ownership | $86,571 | 2 | |
| 2020 | Ownership | $86,571 | 2 | |
| 2019 | Ownership | $86,571 | 2 |
Beside peers
- Ran Schwarzkopf
- California median
- Middle half of California
- National median
In program year 2025, general payments to Ran Schwarzkopf were reported at $429,337. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.
Show as a table
| Year | Ran Schwarzkopf | California median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $200,196 | $161 | $50–$652 | $163 |
| 2020 | $124,080 | $114 | $34–$392 | $114 |
| 2021 | $183,389 | $137 | $41–$509 | $132 |
| 2022 | $248,755 | $152 | $48–$573 | $149 |
| 2023 | $392,600 | $162 | $50–$581 | $160 |
| 2024 | $458,339 | $162 | $52–$583 | $164 |
| 2025 | $429,337 | $172 | $54–$610 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
264
Drug cost
$751
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Meloxicam | Generic | 224 | $611 | |
| Gabapentin | Generic | 12 | $81 | |
| Tramadol Hcl | Generic | 12 | $39 | |
| Amoxicillin | Generic | 16 | $20 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 45 billing codesPaid by Medicare
$453,569
Medicare patients
785
Services billed
3,167
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 73% | |
| Ischemic heart disease | 34% | |
| Diabetes | 30% | |
| Osteoporosis | 26% | |
| Depression | 20% | |
| Cancer | 18% | |
| Chronic kidney disease | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 | Office | 15 | 22 | $9,037 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 113 | 997 | $751 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
907 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.